Alpha 2.0
Login Register
» Journals » Ann Oncol

Annals of Oncology : Official Journal of the European Society for Medical Oncology

The Annals of Oncology is the official journal of the European Society for Medical Oncology. It is a leading international journal that publishes high-quality research and clinical studies in the field of oncology. With a focus on advancing knowledge and improving patient care, the journal covers a wide range of topics including cancer biology, diagnosis, treatment, and supportive care. It serves as a valuable resource for oncologists, researchers, and healthcare professionals worldwide.
Details
Abbr. Ann Oncol
Publisher Elsevier
Start 1990
End Continuing
Frequency Twelve no. a year
p-ISSN 0923-7534
e-ISSN 1569-8041
Country United Kingdom
Language English
Specialty Oncology
Metrics
h-index / Ranks: 219 294
SJR / Ranks: 37 13942
CiteScore / Ranks: 26 63.00
JIF / Ranks: 26 50.5
Recent Articles
1.
Letter to the Editor - Survival Among Patients Treated with Total Mesorectal Excision or Selective Watch-and-Wait After Total Neoadjuvant Therapy: A Pooled Analysis of the CAO/ARO/AIO-12 and OPRA Randomized Phase II Trials
Perez R, Vailati B, Juliao G, Corbi L
Ann Oncol . 2025 Mar; PMID: 40089152
No abstract available.
2.
Redefining Clinical Trial Strategic Design to Support Drug Approval in Medical Oncology
Antonarelli G, Perez-Garcia J, Gion M, Rugo H, Schmid P, Bardia A, et al.
Ann Oncol . 2025 Mar; PMID: 40086733
Randomized clinical trials represent the gold standard for the introduction of innovative therapies in medical oncology, and they provide the highest level of evidence to ascertain the clinical activity of...
3.
European cancer mortality predictions for the year 2025 with focus on breast cancer
Santucci C, Mignozzi S, Levi F, Malvezzi M, Boffetta P, Negri E, et al.
Ann Oncol . 2025 Mar; PMID: 40074664
Background: We predicted the number of cancer deaths and rates for 2025 in the European Union (EU), its five most populous countries, and the UK, focusing on breast cancer. Materials...
4.
Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ cell tumors
Matulewicz R, Baky F, Liso N, Williams B, Porwal S, Assel M, et al.
Ann Oncol . 2025 Mar; PMID: 40073938
Background: Post-chemotherapy retroperitoneal lymph node dissection (pcRPLND) is integral to multimodal treatment of patients with metastatic non-seminomatous germ cell tumors (NSGCT). We review pathologic and long-term outcomes of pcRPLND following...
5.
Advanced cancer: a robust surrogate of cancer mortality in early detection trials?
Sasieni P, Swanton C, Neal R
Ann Oncol . 2025 Mar; PMID: 40073937
No abstract available.
6.
Efficacy assessment in phase I clinical trials: endpoints and challenges
Gouda M, Ballesteros P, Garrido-Laguna I, Rodon J
Ann Oncol . 2025 Mar; PMID: 40049448
The scope of phase I clinical trials in oncology goes beyond the conventional safety evaluation-only objectives of these trials in other specialties. Rather, most first-in-human cancer trials have therapeutic intent,...
7.
Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial
Li J, Wang Z, Chen L, Zhang W, Ma L, Wu J, et al.
Ann Oncol . 2025 Mar; PMID: 40049447
Background: Standard neoadjuvant regimens for HER2-positive breast cancer include trastuzumab and pertuzumab combined with chemotherapy, and the efficacy and safety of third-generation HER2-direted antibody-drug conjugate (ADC) remain to be elucidated....
8.
Reply to Letter to the Editor: 'A phase III randomised trial on the addition of a contact x-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 years results of the OPERA trial'...
Baron D, Ben Dhia S, Gerard J, Doyen J
Ann Oncol . 2025 Mar; PMID: 40037944
No abstract available.
9.
Enhancing Radiation Therapy with PARP Inhibition in Soft Tissue Sarcomas: A Promising Synergy Requiring Specific Attention to Normal Tissues?
Levy A, Clemenson C, Mondini M, Ngo C, Verret B, Faron M, et al.
Ann Oncol . 2025 Feb; PMID: 40010567
No abstract available.
10.
Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials
Dal Pra A, Ghadjar P, Ryu H, Proudfoot J, Hayoz S, Michalski J, et al.
Ann Oncol . 2025 Feb; PMID: 39986927
Background: The SAKK 09/10 trial randomized biochemically recurrent prostate cancer patients to salvage radiation 64 Gy versus 70 Gy, and the NRG/RTOG 0126 randomized intermediate-risk prostate cancer patients to definitive...